Hugo M. Horlings

Dutch Cancer Society — Netherlands

Medicine · Health Sciences

61h-index25.3kcitations352works5.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(105), Cancer Genomics and Diagnostics(86), Cancer Cells and Metastasis(66), Immunotherapy and Immune Responses(52), Ovarian cancer diagnosis and treatment(35)

Publications345 total

Fasting boosts breast cancer therapy efficacy via glucocorticoid activation
Nature·2025· 1 citedOpen Access
Performance Assessment of a Deep Learning–based Algorithm for Ovarian Cancer Histotyping in an Independent Data Set
The American Journal of Surgical Pathology·2025
Spatial Structure of Tumor and Immune Cells Shape Outcomes in ER⁺HER2⁻ and Triple-Negative Breast Cancer
2025Open Access
Label-efficient computational tumour infiltrating lymphocyte assessment in breast cancer (ECTIL): multicentre validation in 2340 patients with breast cancer
The Lancet Digital Health·2025· 3 citedOpen Access
GANs vs. Diffusion Models for Virtual Staining with the HER2match Dataset
Lecture notes in computer science·2025Open Access
Leveraging Adversarial Learning for Pathological Fidelity in Virtual Staining
Lecture notes in computer science·2025Open Access
Training State-of-the-Art Pathology Foundation Models with Orders of Magnitude Less Data
Lecture notes in computer science·2025· 2 cited
421TiP OPTImaL: Optimisation of treatment for patients with low stage triple-negative breast cancer with high stromal tumor-infiltrating lymphocytes
Annals of Oncology·2025
A quantitative comparison between human experts and AI at estimating tumor-stroma ratio
2025Open Access
H&E to IHC virtual staining methods in breast cancer: an overview and benchmarking
npj Digital Medicine·2025· 6 citedOpen Access
Abstract P1-07-30: Phase II adaptive TONIC2 trial to dissect immunomodulatory capacity of doxorubicin or cisplatin induction followed by anti-PD1 in mTNBC
Clinical Cancer Research·2025
Foundation Models in Medical Imaging: A Review and Outlook
arXiv (Cornell University)·2025Open Access
Intratumoral Heterogeneity in Ngfr+ Melanoma Subpopulations Shapes Immune Evasion and Immunotherapy Resistance
2025Open Access
411TiP Novel Immunotherapy strategies for advanced triple-negative breast cancer: TONIC-3 trial
ESMO Open·2025Open Access
193MO Predictive value of FDG-PET/CT and MRI for neoadjuvant immunotherapy (IO) response in early-stage triple-negative breast cancer (eTNBC): Exploratory analysis of the phase II BELLINI trial
ESMO Open·2025Open Access
Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial
Nature Communications·2025· 3 citedOpen Access
Training state-of-the-art pathology foundation models with orders of magnitude less data
arXiv (Cornell University)·2025Open Access
Tumor-infiltrating lymphocytes in breast cancer through artificial intelligence: biomarker analysis from the results of the TIGER challenge
2025Open Access
Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition
2025· 6 citedOpen Access
ECTIL: Label-efficient Computational Tumour Infiltrating Lymphocyte (TIL) assessment in breast cancer: Multicentre validation in 2,340 patients with breast cancer
arXiv (Cornell University)·2025Open Access
page 1 of 18Next →

Frequent Co-authors

Marc J. van de Vijver(19), Marleen Kok(8), Roberto Salgado(7), Lodewyk F.A. Wessels(7), David G. Huntsman(7), Koen Van de Vijver(6), Jorge S. Reis‐Filho(6), René Bernards(5), Christian U. Blank(5), Paula I. González-Ericsson(5), Giancarlo Pruneri(5), Sandra Demaria(5), Christos Sotiriou(5), Sunil Badve(5), Giuseppe Viale(5), Susan Fineberg(5), Stefan Michiels(5), David L. Rimm(5), Stephen M. Hewitt(5), Sibylle Loibl(5)